Driessen, Christoph

Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4

Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J., Ozdian, T., Bartkova, J., Turi, Z., Moudry, P., et al. (2017) · Nature

Ubiquitin and proteasome pathwaysCancer-related Molecular Pathways

Cited by 807

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer

Berner, F., Bomze, D., Diem, S., Ali, O. H., Fässler, M., Ring, S., Niederer, R., Ackermann, C. J., Baumgaertner, P., Pikor, N., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersChemotherapy-related skin toxicity

Cited by 395

Multiple myeloma: patient outcomes in real‐world practice

Yong, K., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Raab, M. S., et al. (2016) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 326

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors

Hasan Ali, O., Berner, F., Bomze, D., Fässler, M., Diem, S., Cozzio, A., Jörger, M., Früh, M., Driessen, C., Lenz, T. L., et al. (2019) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 187

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 48